GCM
PTCT icon

Gladius Capital Management’s PTC Therapeutics PTCT Stock Holding History

Gladius Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-598
Closed -$24K – 479
2022
Q2 		$24K Buy
+598
New +$21K ﹤0.01% 309

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Gladius Capital Management's PTCT Position: Q3 2022 in Review

Gladius Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2022, closing a stake of 598 shares — an estimated $24K sold.

Gladius Capital Management first reported a position in PTCT in Q2 2022 and held it in 1 quarter. The position peaked at $24K in Q2 2022. 212 funds tracked by Wall St. Rank hold PTCT as of Q3 2022.

  • Gladius Capital Management reported no remaining PTC Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Gladius Capital Management sold 598 PTC Therapeutics shares in Q3 2022, an estimated $24K.
  • Gladius Capital Management first reported a position in PTC Therapeutics in Q2 2022 and held it in 1 quarter.
  • Gladius Capital Management's PTC Therapeutics position peaked at $24K in Q2 2022.
  • 212 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2022.

Based on Gladius Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.